


Syndromic respiratory testing. Patient-specific results.

On-demand testing with the Panther Fusion® assay menu addresses the clinical need to differentiate the overlapping symptoms of respiratory pathogens and SARS-CoV-2 during the winter respiratory season and beyond.



Run single or multiple assays from a single patient specimen to detect the most common respiratory pathogens.

The Panther Fusion Respiratory assays.

Right patient. Right test. Right time.



Process 335 Panther Fusion tests or combine Panther Fusion and Aptima® assays for up to 500 tests in 8 hours.



Choose from the most common respiratory pathogens.



Control costs by running only the assays needed.



Deliver comprehensive coverage of target analytes.



Provide comprehensive reactivity and specificity results.



Personalise patient testing from a single sample.



Attain 60-day onboard stability with unit dose, ready-to-use reagents.



Minimise user interaction and return visits to the system with bulk onboard reagents.



Be prepared for the winter respiratory season with Panther Fusion® assays:

a fully-automated, modular approach to syndromic respiratory testing.

Increase efficiency. Reduce costs.

Accurate and timely diagnosis of the cause of respiratory tract infections has a number of benefits for patients and their communities, including:

- Helps reduce the potential for further development of antimicrobial resistance due to antibiotics.1
- Improves patient care and helps decrease costs.^{2,3}
- Provides valued information to public health authorities regarding which viruses are circulating in the community.4
- Assists infection control personnel to provide appropriate measures to minimise nosocomial spread.5

Proven performance and comprehensive design you can trust.

FUSION® SARS-CoV-2/Flu A/B/RSV Assav









High sensitivity and specificity ⁶		
	Sensitivity	Specificity
SARS-CoV-2	98.1%	98.5%
Influenza A	100%	99.6%
Influenza B	98.1%	99.6%
RSV	98.1%	100%
Influenza A	98.8%	99.0%
Influenza B	100%	99.8%
RSV	99.3%	99.0%
Adenovirus	98.3%	97.0%
hMPV	100%	94.6%
RV	90.1%	95.4%
Parainfluenza 1	100%	100%
Parainfluenza 2	100%	100%
Parainfluenza 3	100%	99.6%
Parainfluenza 4	98.1%	100%
Bordetella pertussis	100%	96.8%
Bordetella parapertussis	100%	99.6%

Verified sample collection



- √ BD Universal Viral Transport System
- √ COPAN Universal Transport Medium
- ✓ Remel MicroTest M4, M4RT, M5 or M6 formulations*





*Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Flu A/B/RSV assay validated only for nasopharyngeal swab in viral transport medium and universal transport medium

References: 1. Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing, J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. PMID: 31142607; PMCID: PMC6711893. [page 7] 2. https://www.healthvic.govau/health-advisories/testing-for-respiratory-pathogens Accessed August, 2022. 3. Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing, J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. doi: 10.1

EC REP Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium. EC REP details wherever applicable

Diagnostic Solutions | Hologic.com | euinfo@hologic.com